Jenelle Raynowska, MD
Neurology · San Diego, CANPI 1386176063
Payments from drug & device makers
What this record shows
This record is dominated by grants: $79,773 of the $80,599 with a category attached, or 99.0%. Biogen accounts for 99.0% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2020 at $79,773 and has fallen 99.6% since, to $359 in 2025. Among neurology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 26 payments — averaging $3099.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$80K
- EMD Serono, Inc.$271
- Pharmaessentia USA Corporation$92
- AstraZeneca$69
- Pfizer$63
- Sobi, Inc$60
- plus $220 from 9 others
What the payments were for
- Grants$79,77399%
- Food & beverage$8261%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 3 | $79,824 |
| EMD Serono, Inc. | 2 | $271 |
| Pharmaessentia USA Corporation | 3 | $92 |
| AstraZeneca | 3 | $69 |
| Pfizer | 3 | $63 |
| Sobi, Inc | 2 | $60 |
| Blueprint Medicines Corporation | 2 | $49 |
| AbbVie | 1 | $27 |
| Johnson & Johnson | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| Merz Pharmaceuticals, LLC | 1 | $21 |
| Beone Medicines USA, Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $16 |
| Agios Pharmaceuticals, Inc. | 1 | $16 |
How this compares
$80,599 in reported general payments places this provider in the 90th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 12 | $167,074 |
| Levetiracetam | 55 | $3,373 |
| Gabapentin | 64 | $1,465 |
| Pregabalin | 41 | $820 |
| Topiramate | 13 | $155 |
Paid to pharmacies, not to this prescriber.
Other neurology in San Diego
- Chamindra LavertySan Diego$662K
- Hossein AnsariSan Diego$377K
- Revere KinkelSan Diego$266K
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Regina BerkovichWest Hollywood$3M
- Daniel BandariNewport Beach$2.6M
- Perry ShiehLos Angeles$2.4M
- Sandeep ThakkarIrvine$2M
- David LiebeskindLos Angeles$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.